Early Cancer Detection
The Importance of Early Cancer Detection
Our Early Cancer Detection Blood Tests
Our Multiomics Platform
Clinical Evidence
Clinical Studies
Publications
About
About Us
Team
News
Contact Us
Partnerships
Partnership Opportunities
Careers
Open Positions
freenome logo
Early Cancer Detection
The Importance of Early Cancer Detection
Our Early Cancer Detection Blood Tests
Our Multiomics Platform
Clinical Evidence
Clinical Studies
Publications
About
About Us
Team
News
Contact Us
Partnerships
Partnership Opportunities
Careers
Open Positions
Press Releases
2023
Walgreens and Freenome Establish Partnership to Increase Diversity in Research for the Early Detection of Cancer
June 15, 2023
Freenome Acquires Global Immunodiagnostics Developer Oncimmune Ltd
May 22, 2023
Freenome Adds University Of Chicago As A Partner For Its Vallania Study
April 12, 2023
Freenome Adds Renown Health As Partner For The Sanderson Study
March 28, 2023
Freenome Presents A Subject Population Analysis Of A Clinical Study Using A Multiomics Blood Test For The Early Detection Of Colorectal Cancer
March 6, 2023
Freenome Partners with Geisinger for the Sanderson Study
January 18, 2023
2022
Freenome Presents Research Highlighting The Promise of Identifying Drug-Response Biomarker for DLBCL Patients
December 12, 2022
Freenome Adds Several Community Partners to Clinical Study for the Early Detection of Cancer
November 1, 2022
Freenome Launches Study of Multiple Cancers Pairing Multiomics with Real-World Data
September 6, 2022
Freenome Continues Growth, Adds Three New Leaders
June 2, 2022
Freenome Research Underscores Clinical Utility of Screening Tests That Detect Adenomas
May 25, 2022
Freenome and Morehouse Present Research on Study Participation Among Black Patients
May 23, 2022
Largest Clinical Study Validating a Blood-based Colorectal Screening Test Completes Enrollment
May 10, 2022
Freenome and Merck KGaA, Darmstadt, Germany to Present Data on Combination of Multiomics Profiling and Computational Modeling at AACR Meeting
April 13, 2022
Freenome Presents Research That Highlights the Significance of Detecting Adenomas in Any Test That Screens for Colorectal Cancer
April 11, 2022
Lance Baldo Joins Freenome as Chief Medical Officer
April 4, 2022
Research Highlights Changing Factors that Influence Colorectal Cancer Screening Adherence
March 15, 2022
Freenome Launches the Vallania Study for the Early Detection of Multiple Cancers
February 28, 2022
Freenome Presents Research Highlighting its Multiomics Blood Testing Platform in PREEMPT CRC
January 24, 2022
Significant Investment Accelerates Freenome’s Multiomics Platform for the Early Detection of Cancer
January 11, 2022
2021
Freenome Raises $300M in Series D Financing to Advance Multiomics Platform for Early Cancer Detection
December 7, 2021
Freenome Partners with Siemens Healthineers for Breast Cancer Research
December 1, 2021
Morehouse School of Medicine and Freenome Present Research Demonstrating High Enrollment Rates for African Americans in Clinical Trial
October 27, 2021
Freenome Shows Continued Leadership in Colorectal Cancer Research
October 25, 2021
Research Shows the Clinical Benefits of Detecting Adenomas
June 7, 2021
Freenome Presents Data Revealing Signatures of Immune Checkpoint Inhibitor Treatment Response Found to Be Common Across Kidney, Melanoma, and Lung Cancers
April 10, 2021
2020
PREEMPT CRC Trial for Blood-Based Test to Detect Colon Cancer Has Expanded to Enroll Patients From Anywhere in the Continental U.S. During COVID-19 Pandemic
August 26, 2020
Freenome Closes $270 Million Series C Financing to Advance Novel Multiomics Blood Testing Platform for Early Cancer Detection
August 26, 2020
Freenome Announces Initiation of the PREEMPT CRC Clinical Trial, a Registrational Study for the Early Detection and Prevention of Colorectal Cancer Using a Multiomics Blood Test
May 26, 2020
Freenome Announces Encouraging Performance Data for Its Multiomics Blood Test to Detect Early-Stage Colorectal Cancer in a Prospective, Multi-Center Clinical Study
January 23, 2020
2019
ADC Therapeutics and Freenome Enter Biomarker Development Collaboration
August 26, 2019
Freenome Closes $160 Million Series B Financing to Advance Its Multiomics Blood Testing Platform for Early Cancer Detection
July 24, 2019
Freenome Bolsters Scientific Leadership, Naming Genomic-Medicine Pioneer, Jimmy Lin, As New Chief Scientific Officer
April 30, 2019
2018
Freenome Unveils Promising Early Data on Colorectal Cancer Screening Test at American College of Gastroenterology Annual Meeting
October 9, 2018
Freenome’s IMPACT Advisory Board Brings Strategic Insight and Real-World Experience to AI-Genomics Cancer Tests
July 12, 2018
Christian Doppler Research Grant Awarded to Freenome and the Medical University of Graz to Advance Understanding of Gene Expression Changes in Cancer Using Circulating Biomarkers
May 31, 2018
Freenome and Biognosys Announce Collaboration to Improve Early-Cancer Detection and Treatment
April 24, 2018
Institut Curie and Freenome Announce a Strategic Collaboration in Cell-Free DNA Analysis Using Machine Learning Technology
March 29, 2018
2017
Invitae Chairman Randy Scott Joins Freenome Board of Directors
December 21, 2017
Freenome Announces Formation of Scientific Advisory Board
October 18, 2017
Freenome Announces Series A Extension Led by Section 32
August 28, 2017
Freenome Appoints Abraham Tzou, M.D. Vice President, Regulatory Affairs
August 2, 2017